{"id":"dwc202313-dwc202314","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Muscle weakness"},{"rate":"null","effect":"Dysphagia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They work by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation and reduced muscle spasms.","oneSentence":"DWC202313 and DWC202314 are botulinum toxin type A inhibitors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:10.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic sialorrhea"},{"name":"Upper limb spasticity"}]},"trialDetails":[{"nctId":"NCT06671392","phase":"PHASE3","title":"A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-02-24","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT07260851","phase":"PHASE1","title":"Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-11-05","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT07267221","phase":"PHASE1","title":"Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-12-01","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT06119958","phase":"PHASE1","title":"Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-10-27","conditions":"Drug Drug Interaction","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWC202313, DWC202314","genericName":"DWC202313, DWC202314","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWC202313 and DWC202314 are botulinum toxin type A inhibitors. Used for Chronic sialorrhea, Upper limb spasticity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}